keyword
MENU ▼
Read by QxMD icon Read
search

IL-31

keyword
https://www.readbyqxmd.com/read/29156718/interleukin-31-and-thymic-stromal-lymphopoietin-expression-in-plasma-and-lymph-node-from-hodgkin-lymphoma-patients
#1
Elisa Ferretti, Stefan Hohaus, Arianna Di Napoli, Beatrice Belmonte, Annarosa Cuccaro, Elisa Cupelli, Eugenio Galli, Vittoria Rufini, Gino Tripodi, Giulio Fraternali-Orcioni, Vito Pistoia, Anna Corcione
Hodgkin Lymphoma (HL) is a tumor of B-cell origin characterized by Hodgkin and Reed-Stenberg (H/RS) cells embedded in an inflammatory tissue where numerous cytokines/chemokines contribute to shape the microenvironment, leading to the typical clinical symptoms. We investigated: i) the expression of Interleukin-IL-31 (IL-31) and Thymic Stromal Lymphopoietin (TSLP), two Th2-related cytokines with tumor-promoting and pruritogenic functions, and of the respective receptors in HL invaded lymph nodes by flow cytometry, and ii) the potential association of IL-31/TSLP plasma concentrations with clinical characteristics by ELISA...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29122151/biologic-therapy-for-atopic-dermatitis-moving-beyond-the-practice-parameter-and-guidelines
#2
Mark Boguniewicz
Atopic dermatitis (AD), a common chronic pruritic inflammatory skin disease, impacts the quality of life of patients and caregivers and has become a global health problem. It is increasingly recognized as a disease not only of children but also of adults who may have a persistent or relapsing course from childhood or who develop new-onset adult disease. Besides well-established atopic comorbidities, associations with a number of nonatopic comorbidities have been reported. AD is characterized by both immune dysregulation and epidermal barrier dysfunction...
November 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29116431/correlation-of-il-31-gene-polymorphisms-with-susceptibility-and-clinical-recurrence-of-bladder-cancer
#3
Qin Li, Tielong Tang, Peng Zhang, Chenlu Liu, Yan Pu, Yan Zhang, Huizi Song, Yanyun Wang, Yaping Song, Min Su, Bin Zhou, Lin Zhang
Interleukin-31 is a crucial cytokine triggering inflammation which could be one of the risk factors of tumors. However, data for correlation between IL-31 and tumors are limited. The purpose of our study was to discuss whether genetic polymorphisms of IL-31 were associated with the susceptibility and clinical outcomes of bladder cancer. Our study enrolled 478 controls, 156 non-muscle-invasive bladder cancer (NMIBC) and 138 muscle-invasive bladder cancer (MIBC) patients. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping two single nucleotide polymorphisms (SNPs) of IL-31 gene including rs7977932 and rs4758680...
November 8, 2017: Familial Cancer
https://www.readbyqxmd.com/read/29110391/th2-axis-related-cytokines-in-patients-with-neuromyelitis-optica-spectrum-disorders
#4
Ying Zhang, Xiao-Ying Yao, Mei-Chun Gao, Jie Ding, Rong-Hua Hong, Hua Huang, Lei Zhuang, Yong-Gang Wang, Yong Hao, Yang-Tai Guan
AIMS: Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory autoimmune disease of the central nervous system. Increasing evidence indicates that NMOSD is a Th2- and Th17-dominant disease. IL-25, IL-31, and IL-33 are three newly found Th2-related cytokines, and their roles in the pathogenesis of NMOSD have not been studied. This study aimed to measure the serum levels of IL-25, IL-31, and IL-33 in patients with NMOSD and evaluate their clinical implications. METHODS: Serum was collected from patients with NMOSD (n = 48) and healthy controls (HC, n = 28)...
November 6, 2017: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29050818/decreased-serum-levels-of-scd40l-and-il-31-correlate-in-treated-patients-with-relapsing-remitting-multiple-sclerosis
#5
José de J Guerrero-García, Argelia E Rojas-Mayorquín, Yeminia Valle, Jorge R Padilla-Gutiérrez, Víctor A Castañeda-Moreno, Mario A Mireles-Ramírez, José F Muñoz-Valle, Daniel Ortuño-Sahagún
The CD40/CD40L system is a binding key for co-stimulation of immune cells. Soluble form of CD40L has been widely studied as marker of inflammatory and autoimmune diseases. Here we analyze serum concentrations of sCD40L, as well as 14 cytokines, in patients with Multiple Sclerosis (MS) treated with Glatiramer acetate or Interferon beta. In the healthy control group, we found in serum a highly positive correlation between sCD40L and Interleukin (IL)-31, an anti-inflammatory Th2 cytokine. Additionally, an important reduction in IL-31 and sCD40L serum levels, as well as a significant reduction in CD40 mRNA expression and complete depletion of CD40L mRNA, detected from peripheral blood cells, was found in treated patients with MS...
October 5, 2017: Immunobiology
https://www.readbyqxmd.com/read/29046191/interleukin-31-and-skin-diseases-a-systematic-review
#6
Sebastiano Gangemi, Sebastiano Quartuccio, Marco Casciaro, Giovanni Trapani, Paola Lucia Minciullo, Egidio Imbalzano
BACKGROUND: Although the pathophysiology of pruritus has been extensively studied in recent years, with many resultant advancements, management of pruritus is still enigmatic, particularly in chronic cutaneous diseases, such as atopic dermatitis, chronic urticaria, allergic contact dermatitis, cutaneous T-cell lymphoma, and uremic pruritus. The recent finding of the involvement of interleukin (IL) 31 in the pathogenesis of chronic pruritus has provided a novel approach to the management of chronic inflammatory skin disorders...
November 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29020907/atopic-dermatitis-the-new-frontier
#7
REVIEW
Victoria R Harris, Alan J Cooper
Atopic dermatitis (AD) is the most common inflammatory skin condition in adults and children. AD is a chronic disease that has a considerable negative impact on the quality of life of patients and their families. Most cases of AD may be effectively treated with topical therapies that are directed at decreasing cutaneous inflammation and alleviating pruritus. These therapies include emollients, antihistamines, topical corticosteroids, topical calcineurin inhibitors and antimicrobial and antiseptic measures; more refractory cases may require additional oral immunosuppression (eg, cyclosporine, azathioprine, methotrexate and mycophenolate)...
October 16, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28990098/anti%C3%A2-inflammatory-effect-of-amomum%C3%A2-xanthioides-in-a-mouse-atopic-dermatitis-model
#8
Young-Ae Choi, Jin Kyeong Choi, Yong Hyun Jang, Soyoung Lee, Sang-Rae Lee, Jung Ho Choi, Jee Hun Park, Tae-Yong Shin, Sang-Hyun Kim
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder. The present study investigated the effects of Amomum xanthioides extract (AXE) on AD‑like skin inflammation using a Dermatophagoides farinae extract (DFE) and 2,4‑dinitrochlorobenzene (DNCB)‑induced mouse AD model. Hematoxylin and eosin staining results demonstrated that repeated DFE/DNCB exposure markedly increased the thickening of the dermis and epidermis, in addition to the infiltration of eosinophils and mast cells. However, oral administration of AXE reduced these histopathological alterations in a dose‑dependent manner...
December 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28989146/epicutaneous-sensitization-with-ovalbumin-staphylococcal-enterotoxin-b-and-vitamin-d-analogue-induces-%C3%A2-atopic-dermatitis-in-mice
#9
Lina Tan, Jianyun Lu, Meilin Chen, Yaping Xiang, Qingmei Cheng, Yunsheng Liang, Jinhua Huang, Jian Huang, Jing Chen, Lihua Gao
To illuminate a method for establishment of a cost-efficient atopic dermatitis (AD) mouse model by topical application of ovalbumin (OVA), super-antigen staphylococcal enterotoxin B (SEB), and calcipotriene ointment (CO) on the back of BALB/c mice.
 Methods: Experimental mice were topically treated with OVA/SEB or OVA/SEB/CO every other day during 15 days of induction. Clinical alterations on the skin area were monitored every other day. Epidermal thickness were measured by reflectance confocal microscope (RCM) before harvest...
September 28, 2017: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/28983982/investigation-of-the-correlation-of-serum-il-31-with-severity-of-dermatitis-in-an-experimental-model-of-canine-atopic-dermatitis-using-beagle-dogs
#10
Rosanna Marsella, Kim Ahrens, Rachel Sanford
BACKGROUND: IL-31 is a cytokine that is believed to play an important role in atopic dermatitis (AD). IL-31 levels positively correlate with disease severity in children with AD. Currently, there is no study that has investigated such a correlation in atopic dogs. HYPOTHESIS/OBJECTIVE: The purpose of this study was to evaluate the correlation between IL-31 serum levels and severity of dermatitis. It was hypothesized that a positive correlation exists between severity of AD and circulating levels of IL-31...
October 6, 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28969616/assessment-of-biomarkers-using-multiplex-assays-in-aqueous-humor-of-patients-with-diabetic-retinopathy
#11
Hui Chen, Xiongze Zhang, Nanying Liao, Feng Wen
BACKGROUND: With the high prevalence of type 2 diabetes, diabetic retinopathy (DR) has become a leading health problem worldwide. The pathogenesis of DR is complex and several vascular, inflammatory, and neuronal mechanisms are involved. The purpose of this study was to assess the levels of immune and inflammatory biomarkers in the aqueous humor of patients with different severities of DR and to analyze the correlations between Interleukin-6 (IL-6) and these biomarkers, and between IL-6 and the severity of the disease...
October 2, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28906040/a-blinded-randomized-clinical-trial-evaluating-the-efficacy-and-safety-of-lokivetmab-compared-to-ciclosporin-in-client-owned-dogs-with-atopic-dermatitis
#12
Hilde Moyaert, Leen Van Brussel, Stasia Borowski, Monica Escalada, Sean P Mahabir, Rodney R Walters, Michael R Stegemann
BACKGROUND: Lokivetmab is an injectable anti-canine-IL-31 monoclonal antibody to treat clinical manifestations of atopic dermatitis (AD) in dogs. HYPOTHESIS/OBJECTIVES: To characterize the efficacy and safety of lokivetmab, and to demonstrate its noninferiority to ciclosporin under field conditions. ANIMALS: Dogs with chronic AD (n = 274) were enrolled from 40 practices in Belgium, The Netherlands, France and Germany. METHODS: Animals were randomized (1:1) to oral ciclosporin (5 mg/kg/once daily) or monthly injectable lokivetmab (1-3...
September 14, 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28887947/therapeutic-pipeline-for-atopic-dermatitis-end-of-the-drought
#13
REVIEW
Amy S Paller, Kenji Kabashima, Thomas Bieber
Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic immunosuppressants. The pipeline of more targeted topical and systemic therapies is expanding based on our growing understanding of the mechanism for AD and is particularly focused on suppressing the skewed immune activation. Most agents are in phase 2 clinical trials. Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available in late 2016 in the United States for mild-to-moderate AD, with other PDE4 inhibitors, an agonist of the aryl hydrocarbon receptor, Janus kinase inhibitors, and commensal organisms also in trials for topical application...
September 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28887844/house-dust-mite-allergens-der-f-and-der-p-induce-il-31-production-by-blood-derived-t-cells-from-atopic-dermatitis-patients
#14
Krisztina Szegedi, Amanda van Lier, Pieter C Res, Saskia Chielie, Jan D Bos, Sanja Kezic, Maritza A Middelkamp-Hup, Rosalie M Luiten
No abstract text is available yet for this article.
September 8, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28861617/novel-therapeutic-approaches-to-atopic-dermatitis
#15
REVIEW
Katarzyna Osinka, Karolina Dumycz, Bartłomiej Kwiek, Wojciech Feleszko
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. The number of people affected by AD is relatively high and seems to be rising. Although mild and moderate forms of the disease can be well controlled by the use of emollients, topical corticosteroids, and topical calcineurin inhibitors, treatment of severe is still a huge challenge. The new hope is biologic drugs, magic bullets in allergy, targeted at different points of the complex pathomechanism of inflammation in AD. In this review, novel biologic therapies are discussed, including recombinant monoclonal antibodies directed against various interleukin pathways (such as IL-4, IL-13, TSLP, IL-31, and IL-12/23), on immunoglobulin E, molecules acting as T cells, B cells, etc...
August 31, 2017: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/28853956/new-and-emerging-targeted-systemic-therapies-a-new-era-for-atopic-dermatitis
#16
Dylan E Lee, Ashley K Clark, Khiem A Tran, Vivian Y Shi
PURPOSE: This is a review of emerging targeted, systemic therapies for atopic dermatitis (AD). The information presented aims to provide dermatologists with updated therapeutic options, stimulate academic interest, and spark future research. MATERIALS AND METHODS: Extensive search of ClinicalTrials.gov, the National Eczema Association, and PubMed was performed for clinical trials examining the effect of emerging targeted, systemic therapies in patients with AD. Results were included if they demonstrated efficacy in reversing AD symptoms...
August 30, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28808661/the-role-of-intereukin-31-in-pathogenesis-of-itch-and-its-intensity-in-a-course-of-bullous-pemphigoid-and-dermatitis-herpetiformis
#17
Lilianna Kulczycka-Siennicka, Anna Cynkier, Elżbieta Waszczykowska, Anna Woźniacka, Agnieszka Żebrowska
Itch which is one of the major, subjective symptoms in a course of bullous pemphigoid and dermatitis herpetiformis makes those two diseases totally different than other autoimmune blistering diseases. Its pathogenesis is still not fully known. The aim of this research was to assess the role of IL-31 in development of itch as well as to measure its intensity. Obtained results, as well as literature data, show that lower concentration of IL-31 in patients' serum may be correlated with its role in JAK/STAT signaling pathway which is involved in development of autoimmune blistering disease...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28782487/natalizumab-changes-the-peripheral-profile-of-the-th17-panel-in-ms-patients-new-mechanisms-of-action
#18
Rodica Ioana Bălașa, Simu Mihaela, Septimiu Voidăzan, Laura Iulia Bărcuțean, Zoltan Bajko, Adina Huțanu, Iunius Simu, Smaranda Maier
INTRODUCTION: Natalizumab (NAT) is an effective treatment for relapsing remitting multiple sclerosis (RRMS),as it makes the blood-brain-barrier impenetrable bybinding to the α4integrin subunit. The objectives of our study were to find new peripheral mechanisms of action of NAT and new biomarkers of treatment response. MATERIAL AND METHODS: We prospectively assessed the serum levels of 15 cytokines from the Th17 Cytokine Panelusing Bio-plex Pro Human in a group of 29 RRMS patients treated with NAT and 29 healthy subjects(HS) at inclusion and after 8 months of NAT treatment...
August 7, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28698528/inflammatory-and-noninflammatory-itch-implications-in-pathophysiology-directed-treatments
#19
REVIEW
Lai-San Wong, Tiffany Wu, Chih-Hung Lee
Itch is the main chief complaint in patients visiting dermatologic clinics and has the ability to deeply impair life quality. Itch results from activation of cutaneous nerve endings by noxious stimuli such as inflammatory mediators, neurotransmitters and neuropeptides, causing itch signal transduction from peripheral skin, through the spinal cord and thalamus, to the brain cortex. Primarily noninflammatory diseases, such as uremic pruritus, cause itch through certain pruritogens in the skin. In inflammatory skin diseases, atopic dermatitis (AD) is the prototypic disease causing intensive itch by aberrant skin inflammation and epidermal barrier disruption...
July 10, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28670717/emerging-role-of-interleukin-31-and-interleukin-31-receptor-in-pruritus-in-atopic-dermatitis
#20
REVIEW
Masutaka Furue, Kazuhiko Yamamura, Makiko Kido-Nakahara, Takeshi Nakahara, Yoshinori Fukui
Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH 2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH 2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD...
July 3, 2017: Allergy
keyword
keyword
85649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"